FACTORS INFLUENCING THE SELECTION OF DIRECT ACTING ANTIVIRALS IN THE TREATMENT OF GENOTYPE 1 HEPATITIS C VIRUS INFECTION
CP-215
OPTIMISATION OF RESTRICTED ANTIBIOTICS IN THE TREATMENT OF URINARY TRACT INFECTIONS
CP-213
HOSPITAL PHARMACISTS INTERVENTIONS ON ANTIEMETIC APPROPRIATENESS IN PAEDIATRIC ONCOLOGY IN A UNIVERSITY HOSPITAL CENTRE
CP-212
EFFECTIVENESS AND SAFETY OF NEW DIRECT ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C INFECTION: PRELIMINARY DATA IN A COINFECTED HIV/HCV POPULATION
CP-210
ECONOMIC IMPACT OF OBESITY AND OVERWEIGHT IN THE INFLIXIMAB TREATMENT IN A TERTIARY HOSPITAL
CP-208
PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATINE COMBINATION IN THE TREATMENT OF RECURRENT OVARIAN CARCINOMA. COMPARATIVE LONG TERM EFFECTIVENESS
CP-204
THERAPEUTIC OPTIMISATION OF ELDERLY PRESCRIPTIONS: TARGETED PHARMACEUTICAL DISCHARGE LETTER
CP-202
SAFETY AND EFECTIVENESS OF TOPICAL 10% NACETYLCYSTEINE NACETYLCYSTEINE CONGENITAL LAMELLAR ICHTYOSIS AND EPIDERMOLYTIC ICHTYOSIS IN CHILDREN
CP-201
RISK MANAGEMENT IN CIRCUIT OF MEDICATION: WHAT ROLE OF PHARMACIST
CP-199
EFFECTIVENESS AND SAFETY OF ECULIZUMAB IN ATYPICAL HAEMOLYTIC URAEMIC SYNDROME ANDTHROMBOTIC MICROANGIOPATHY
CP-197
IVERMECTIN ENEMA ELABORATION FOR THE TREATMENT OF STRONGYLOIDES HYPERINFECTION
CP-195
CONTRIBUTION OF CLINICAL PHARMACIST IN AN EXPERIENCE FEEDBACK COMMITTEE: OUTCOMES AT 9 MONTHS OF ANALYSIS OF DRUG PRESCRIPTIONS FOR PATIENT ‘FALLERS’
CP-193
DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC LIVER DISEASE: A SNAPSHOT BY CLINICAL PHARMACIST
CP-191
IMPACT OF MEDICATION RECONCILIATION AT HOSPITAL ADMISSION IN SURGICAL PATIENTS
CP-190
INCIDENCE AND RISK FACTORS ASSOCIATED WITH TREATMENT FAILURE IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
